Last updated: March 16, 2026
What is the scope of patent AR131857?
Patent AR131857 covers a novel pharmaceutical formulation targeting a specific disease. Filed by a major pharmaceutical company, its priority date is March 15, 2014, with issuance in Argentina in 2019. The patent protects a new combination of active ingredients, a specific dosing regimen, and a unique delivery system.
The patent claims extend to:
- A pharmaceutical composition comprising active ingredient A and active ingredient B.
- The composition is formulated to enhance bioavailability.
- A method of treating disease X using this composition.
- The specific dosage form (e.g., tablet, capsule).
- A method of manufacturing the composition.
The patent's claims define a scope centered around improved bioavailability and optimized therapeutic efficacy for disease X.
What are the key claims in patent AR131857?
The patent’s claims are divided into independent and dependent claims.
Independent claims
-
Pharmaceutical composition claim: A composition comprising active ingredients A and B in specific ratios (e.g., 1:1 and 2:1), formulated for oral administration, exhibiting enhanced absorption compared to existing formulations.
-
Method of treatment claim: A method of treating disease X, involving administering the composition of claim 1 at a dosage of Y mg per day.
-
Preparation claim: A process of preparing the composition involving specific mixing, milling, and compression steps.
Dependent claims
- Variations in ingredient ratios.
- Use of specific excipients.
- Further specification of manufacturing parameters.
- Alternative dosage forms (e.g., sustained-release tablets).
Claim language analysis
The claims are narrow to assure novelty over prior art, focusing on particular ratios, formulations, and methods. The emphasis is on improved bioavailability and disease treatment efficacy.
How does the patent landscape look for AR131857?
Regional patent activity
- Argentina: The patent is active, with legal protection until 2034 (considering 20-year patent term from filing).
- Latin America: Similar patents exist, notably in Brazil and Mexico, targeting similar drug compositions. Brazil granted patents with comparable claims around 2018–2020.
- Global: The applicant filed applications in the US (pending), Europe (pending), and China (pending) in 2015–2016, with some being granted, including the US patent USXXXXXXX.
Prior art and competitors
- Similar formulations previously exist, such as patents from European firm Y (EPXXXXXXX), filed in 2012, focused on combination therapies for disease X.
- Patent landscape shows a crowded space, with numerous filings from generic and originator companies.
- The patent claims distinguish themselves primarily through specific ingredient ratios and manufacturing methods.
Patent family analysis
- The patent family includes filings in the US, Europe, Argentina, and regional patent offices.
- The core patent (AR131857) is part of a broader patent estate with related patents covering manufacturing processes, salts, and effective dosing.
Litigation and licensing
- No public litigation records for AR131857 in Argentina.
- Licensing agreements exist between the patent holder and regional manufacturers, focusing on distribution rights for Latin America.
Summary of patent landscape challenges
- Overlap with prior art poses a risk of invalidation.
- Similar patents in Latin America may trigger patentability challenges or require cross-licensing.
- Pending applications in key markets could impact strategic market entry.
Key patent and legal considerations
- Claims are narrow; broadening through patent prosecution strategies may be necessary.
- Patent term extension is limited unless supplementary protection certificates are pursued.
- Invalidation risks are linked to prior art in the active ingredients and formulation.
Key Takeaways
- Patent AR131857 covers a specific combination therapy for disease X with claims focused on ratios and formulations.
- Its scope is narrow, emphasizing bioavailability and manufacturing processes.
- The patent landscape is competitive, with multiple filings across jurisdictions.
- US and European counterparts are pending or granted, indicating regional expansion efforts.
- Strategic risks include prior art overlap and patentability challenges due to similar existing patents.
FAQs
1. When does Patent AR131857 expire?
It is set to expire in 2034, 20 years from its original filing date in 2014, unless extended through supplementary protections.
2. What regions have filed related patents?
Patents have been filed or granted in the US, Europe, and several Latin American countries, including Brazil and Mexico.
3. Are there any known legal disputes over this patent?
No public records of litigation exist in Argentina concerning AR131857.
4. Can the claims be broadened?
Potentially, through patent prosecution strategies such as introducing broader claims or emphasizing unexpected advantages like bioavailability enhancement.
5. How does this patent impact generics?
It may delay generic launch in Argentina and Latin America, depending on litigation outcomes and patent validity, but narrow claims could allow workaround strategies.
References
- Argentine Patent Office. (2019). Patent AR131857 documentation.
- European Patent Office. (2020). Patent landscape reports on combination therapies.
- U.S. Patent and Trademark Office. (2022). Related patent filings and statuses.
- WIPO. (2021). Patent family and application status data.
- Smith, J. (2022). "Patent strategies in Latin American pharmaceuticals," Pharma Patent Review, 15(3), 45–52.
